Integrating mpMRI and 18F-PSMA PET/CT via the composite P score to detect clinically significant prostate cancer in the PSA gray zone
Biopsy triage remains challenging in men with prostate-specific antigen (PSA) levels of 4.0–10.0 ng/mL because multiparametric MRI (mpMRI) may yield equivocal findings and reader-dependent interpretation. Prostate-specific membrane antigen (PSMA) PET/CT may provide complementary molecular information. We evaluated the diagnostic performance and incremental value of the composite P score, which integrates PI-RADS and PRIMARY scores, for detecting clinically significant prostate cancer (csPCa) in the PSA gray zone. This two-center retrospective study included 178 men with PSA 4.0–10.0 ng/mL who underwent mpMRI, 18 F-PSMA PET/CT, and biopsy between January 2021 and December 2024. Junior and senior radiologists independently assigned Prostate Imaging Reporting and Data System (PI-RADS) scores. A single PRIMARY score was assigned for PSMA PET/CT based on two independent nuclear medicine reads, with discrepancies adjudicated. Composite P scores combined each radiologist’s PI-RADS assessment with the PRIMARY score. csPCa was defined as Gleason score ≥ 3 + 4 according to prostate biopsy. Performance was assessed using area under the curve (AUC), net reclassification improvement (NRI), and decision curve analysis (DCA). csPCa was detected in 125/178 patients (70.2%). Compared with PI-RADS alone, the composite P score showed a higher AUC for the junior reader (0.769 vs. 0.661; P = 0.014), while the difference was not significant for the senior reader (0.805 vs. 0.744; P = 0.167). At the threshold of ≥ 3, the composite P score achieved 100% sensitivity (125/125) for both readers. NRI was significant for the junior reader (0.175; P = 0.010) but not for the senior reader. DCA showed higher estimated net benefit than PI-RADS alone across clinically relevant threshold probabilities for both readers. The composite P score showed favorable performance for csPCa in the PSA gray zone. Integrating 18 F-PSMA PET/CT with mpMRI may provide complementary diagnostic information for biopsy triage in selected patients.
Authors
- Yachao Liu
- Chen Wen
- 陳玉玲
- Wang Zhongyi (ORCID: https://orcid.org/0000-0002-7616-6619)
- Weilong Li (ORCID: https://orcid.org/0000-0002-7913-5260)
- Xiaojing Zhang
- Haiyi Wang (ORCID: https://orcid.org/0000-0002-0717-1748)
- Jian Zhao
- Xu Bai
- XiaoHui Ding
- HongHao Xu
- RuiMin Wang
- BaiChuan Liu
Institutions
- Capital Medical University (CN)
- Chinese PLA General Hospital (CN)
- Yuhuangding Hospital (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- BMC Medical Imaging
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s12880-026-03042-3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00